Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Venglustat - Sanofi

Next Previous
Drug Profile

Venglustat - Sanofi

Alternative Names: Genz-682452-AA; Genz-682452-AU; GZ-402671; GZ/SAR402671; GZ/SAR402671A; Ibiglustat; SAR-402671; SAR402671A; Venglustat malate; Venglustat malate - Sanofi

Latest Information Update: 05 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi; Sanofi Genzyme
  • Class Antiparkinsonians; Azabicyclo compounds; Carbamates; Small molecules; Thiazoles; Urologics
  • Mechanism of Action Glucosylceramide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycystic kidney disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Fabry's disease; Gaucher's disease type III; GM2 gangliosidoses; Polycystic kidney disease
  • Phase II Gaucher's disease
  • Discontinued Parkinson's disease

Most Recent Events

  • 02 Feb 2026 Efficacy and advers evenet data from phase III trials in Gaucher's disease released by Sanofi
  • 26 Dec 2024 Genzyme terminates phase-III AMETHIST trials in GM2 gangliosidoses (In adolescents, In children, In adults) in US, Germany, Portugal, France, the UK, Argentina, Austria, Brazil, Czech Republic, Italy, Japan, Russia, Spain, Turkey due to the absence of positive trends on clinical endpoints (PO) (NCT04221451)
  • 19 Feb 2024 Sanofi announces intention to submit regulatory application for Gaucher's disease (type 3) in 2026 or later (Sanofi pipeline, February 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top